GLUE Stock Analysis: Monte Rosa Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.044m USD | 12M Return: 391% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Monte Rosa Therapeutics (NASDAQ: GLUE) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, founded in 2019. The company focuses on developing orally bioavailable molecular glue degraders (MGDs), a therapeutic modality that leverages the bodys natural protein degradation pathways to selectively eliminate disease-relevant proteins. As a clinical-stage biotech in the GICS Biotechnology sub-industry, Monte Rosa is pre-commercial and therefore depends on capital markets and partnership revenues rather than product sales.
The companys pipeline includes MRT-2359 for MYC-driven tumors, MRT-6160 for neurologic and systemic autoimmune and inflammatory diseases, and MRT-8102 for inflammatory diseases driven by IL-1a, IL-1ß, IL-18, and damage-associated molecular patterns. Additional programs target CDK2 across multiple cancer types, as well as indications in immunology, inflammation, oncology, cardiovascular, metabolic, and genetic diseases. Discovery efforts are supported by QuEEN, the companys proprietary target-centric platform for rational MGD design.
Monte Rosa has established strategic collaboration and licensing agreements with F. Hoffmann-La Roche Ltd. and Novartis, which are typical structures for clinical-stage biotechs seeking to share development risk and fund late-stage programs. The company went public on June 24, 2021.
- MRT-2359 Phase 1 cancer data readout catalyzes stock
- Roche and Novartis collaboration milestones offset cash burn
- Molecular glue pipeline faces Kymera and Arvinas competition
| Net Income: -130.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -21.87 > 1.0 |
| NWC/Revenue: 1.41k% < 20% (prev 171.2%; Δ 1.24k% < -1%) |
| CFO/TA -0.02 > 3% & CFO -14.7m > Net Income -130.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.5m) vs 12m ago -20.99% < -2% |
| Gross Margin: 80.59% > 18% (prev 94.91%; Δ -14.32% > 0.5%) |
| Asset Turnover: 7.60% > 50% (prev 40.56%; Δ -32.96% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.82 (Total Current Assets 677.5m - Total Current Liabilities 71.0m) / Total Assets 736.4m |
| B: -0.71 (Retained Earnings -521.7m / Total Assets 736.4m) |
| C: -0.23 (EBIT TTM -131.9m / Avg Total Assets 564.8m) |
| D: 2.43 (Book Value of Equity 521.9m / Total Liabilities 214.5m) |
| Altman-Z'' = 4.08 = AA |
| DSRI: 3.0 (Receivables 4.61m/1.41m, Revenue 43.0m/159.5m) |
| GMI: 1.18 (GM 94.91% / 80.59%) |
| AQI: 0.58 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.27 (Revenue 43.0m / 159.5m) |
| TATA: -0.16 (NI -130.0m - CFO -14.7m) / TA 736.4m) |
| Beneish M = -2.01 (Cap -4..+1) = BB |
As of July 08, 2026, the stock is trading at USD 24.40 with a total of 1,303,445 shares traded. Over the past week, the price has changed by +2.09%, over one month by +43.53%, over three months by +42.52% and over the past year by +390.95%.
Current recommended Stop Loss: 22.70 (which is 7% or 1.2 ATR below the current price).
Monte Rosa Therapeutics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy GLUE.
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 32.3 | 32.5% |
P/E Forward = 10.02
P/S = 47.5963
P/B = 3.9171
Revenue TTM = 43.0m USD
EBIT TTM = -131.9m USD
EBITDA TTM = -123.5m USD
Long Term Debt = 34.6m USD (estimated: total debt 39.1m - short term 4.48m)
Short Term Debt = 4.48m USD (from shortTermDebt, last quarter)
Debt = 39.1m USD (from shortLongTermDebtTotal, last quarter) (leases 39.1m already included)
Net Debt = -521.9m USD (calculated: Debt 39.1m - CCE 561.0m)
Enterprise Value = 1.52b USD (2.04b + Debt 39.1m - CCE 561.0m)
Interest Coverage Ratio = unknown (Ebit TTM -131.9m / Interest Expense TTM 0.0)
EV/FCF = -14.21x (Enterprise Value 1.52b / FCF TTM -107.1m)
FCF Yield = -7.04% (FCF TTM -107.1m / Enterprise Value 1.52b)
FCF Margin = -249.4% (FCF TTM -107.1m / Revenue TTM 43.0m)
Net Margin = -302.7% (Net Income TTM -130.0m / Revenue TTM 43.0m)
Gross Margin = 80.59% ((Revenue TTM 43.0m - Cost of Revenue TTM 8.34m) / Revenue TTM)
Gross Margin QoQ = 51.81% (prev 24.92%)
Tobins Q-Ratio = 2.07 (Enterprise Value 1.52b / Total Assets 736.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 39.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -104.2m (EBIT -131.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.58 (Total Current Assets 677.5m / Total Current Liabilities 78.9m)
Debt / Equity = 0.07 (Debt 39.1m / totalStockholderEquity, last quarter 521.9m)
Debt / EBITDA = 4.22 (negative EBITDA) (Net Debt -521.9m / EBITDA -123.5m)
Debt / FCF = 4.87 (negative FCF - burning cash) (Net Debt -521.9m / FCF TTM -107.1m)
Total Stockholder Equity = 317.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.02% (Net Income -130.0m / Total Assets 736.4m)
RoE = -40.99% (Net Income TTM -130.0m / Total Stockholder Equity 317.2m)
RoCE = -37.49% (EBIT -131.9m / Capital Employed (Equity 317.2m + L.T.Debt 34.6m))
RoIC = -15.60% (negative operating profit) (NOPAT -104.2m / Invested Capital 667.7m)
WACC = 13.07% (E(2.04b)/V(2.08b) * Re(13.32%) + D(39.1m)/V(2.08b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.32% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 35.96 | Cagr: 6.46%
[DCF] Fair Price = unknown (Cash Flow -107.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.17 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.37 | Chg30d=-0.16% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.38 | Chg30d=-0.08% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=+0.04% | Revisions=-22% | GrowthEPS=-246.0% | GrowthRev=-64.0%
EPS next Year (2027-12-31): EPS=-1.81 | Chg30d=+0.03% | Revisions=-22% | GrowthEPS=-14.0% | GrowthRev=+30.8%
[Analyst] Revisions Ratio: -17% (up=8, down=12)